Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Mectizan Donation Program - highlights from 2005.

Mary M Alleman1, Nana A Y Twum-Danso, Björn I Thylefors

  • 1The Mectizan Donation Program, 750 Commerce Drive, Suite 400, Decatur, GA 30030, USA. malleman@taskforce.org

Filaria Journal
|September 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reaching Never- and Incompletely-Vaccinated Children with Routine Immunization: A Proof-of-Concept Activity Using Geo-Referenced Microplans in Two Health Zones in Maniema Province, Democratic Republic of the Congo.

Vaccines·2026
Same author

The Value - and the Values - of Listening.

Mayo Clinic proceedings·2025
Same author

Progress Toward Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Region of the Americas, 2012-2022.

MMWR. Morbidity and mortality weekly report·2024
Same author

Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - World Health Organization African Region, 2016-2021.

MMWR. Morbidity and mortality weekly report·2023
Same author

Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.

Vaccine·2023
Same author

Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.

MMWR. Morbidity and mortality weekly report·2021
Same journal

Contribution of migrant coffee labourers infected with Onchocerca volvulus to the maintenance of the microfilarial reservoir in an ivermectin-treated area of Mexico.

Filaria journal·2007
Same journal

Epidemiology and psycho-social aspects of onchocercal skin diseases in northeastern Nigeria.

Filaria journal·2007
Same journal

Contributions of different mosquito species to the transmission of lymphatic filariasis in central Nigeria: implications for monitoring infection by PCR in mosquito pools.

Filaria journal·2007
Same journal

Monitoring lymphatic filariasis interventions: Adult mosquito sampling, and improved PCR - based pool screening method for Wuchereria bancrofti infection in Anopheles mosquitoes.

Filaria journal·2007
Same journal

The geographical distribution of lymphatic filariasis infection in Malawi.

Filaria journal·2007
Same journal

Social mobilisation, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka.

Filaria journal·2007
See all related articles

Merck & Co., Inc. has donated Mectizan (ivermectin) for onchocerciasis and lymphatic filariasis (LF) elimination since 1987 and 1998, respectively. Mass treatment programs in Africa, Latin America, and Yemen utilize these donations, facing challenges in LF elimination expansion.

Area of Science:

  • Global Health
  • Infectious Diseases
  • Drug Donation Programs

Background:

  • The Mectizan Donation Program, established by Merck & Co., Inc. in 1987, provides ivermectin (Mectizan) for onchocerciasis treatment.
  • Since 1998, Mectizan has also been donated for lymphatic filariasis (LF) elimination in co-endemic regions, often co-administered with albendazole donated by GlaxoSmithKline.
  • The Mectizan Expert Committee/Albendazole Coordination serves as the scientific advisory body for these donation programs.

Purpose of the Study:

  • To review the scope and impact of Mectizan donations for onchocerciasis and LF elimination programs.
  • To highlight the scale of Mectizan and albendazole treatments approved in 2005 for mass treatment initiatives.
  • To identify challenges and provide recommendations for LF elimination programs, particularly in co-endemic areas.

Related Experiment Videos

Main Methods:

  • Analysis of approved Mectizan treatments for onchocerciasis and co-administered albendazole/Mectizan treatments for LF in 2005.
  • Review of the geographical distribution and program participation (e.g., African Programme for Onchocerciasis Control, Onchocerciasis Control Programme in West Africa, Programs to Eliminate LF).
  • Inclusion of recent recommendations for drug co-administration in areas with co-endemic LF, loiasis, and onchocerciasis.

Main Results:

  • In 2005, over 62 million Mectizan treatments were approved for onchocerciasis mass treatment in Africa, Latin America, and Yemen.
  • Approximately 97% of onchocerciasis treatments were allocated to countries within the African Programme for Onchocerciasis Control and the former Onchocerciasis Control Programme in West Africa.
  • Over 42 million treatments of co-administered albendazole and Mectizan were approved for LF elimination programs in Africa and Yemen.

Conclusions:

  • Mass treatment programs utilizing Mectizan donations are ongoing in all 33 onchocerciasis-endemic countries.
  • Ongoing LF elimination programs using albendazole and Mectizan cover 35% of the expected endemic countries.
  • Expansion of LF elimination programs is hindered by resource limitations, mapping difficulties, and the co-endemicity of LF with loiasis.